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 Aim for a systolic blood pressure lower than the cur-
rent recommended goal of 140 mm Hg.
 Optimum systolic blood pressure should be targeted to
120–130 mm Hg, especially in nondiabetic hyperten-
sive patients with significant risk factors.
 Advantages of aggressive treatment to levels
<120 mm Hg are still unclear.
 Lifestyle modifications rather than initiation of antihy-
pertensive drug treatment should be advocated in indi-
viduals with high-normal blood pressure and no
history of cardiovascular events.
The Systolic Blood Pressure Intervention Trial
(SPRINT)1 has had a major impact in the field of hyperten-
sion and cardiovascular medicine—not only has it clearly
shown increased cardiovascular benefit when systolic blood
pressure is targeted to lower levels (<120 mm Hg) than
currently recommended levels by most major guidelines
(<140 mm Hg), but it has reinvigorated interest in hyper-
tension in clinical and preventive medicine. Since the
publication of SPRINT in November 2015, there have
been over 150 publications with ‘‘SPRINT’’ and ‘‘blood
pressure/hypertension’’ as keywords (Pubmed). Many of
these articles have addressed the issue of just how low
blood pressure should be targeted, and there is heated
debate as to whether and how the SPRINT results will
impact change in current hypertension guidelines.
While it is well known that the risk of cardiovascular dis-
ease increases as blood pressure increases and that blood
pressure lowering reduces this risk in patients with hyper-
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ated and what is the optimal systolic blood pressure that
should be strived for to prevent or reduce hypertension-
associated adverse consequences? The fear of reducing
blood pressure too low such that patients are at risk of
stroke, transient ischemic attack, or renal ischemia is as
important as the concerns of not lowering blood pressure
enough to prevent the risk of stroke, heart failure, or coro-
nary events in hypertensive patients.
The SPRINT results have provided robust data demon-
strating that aiming for systolic blood pressure of
<120 mm Hg with intensive treatment using standard
antihypertensive drugs results in lower rates of composite
primary outcome of nonfatal and fatal cardiovascular
events compared with treating to the standard target of
<140 mm Hg.1 Specifically, in the intensively treated
cohort, the primary composite outcome was reduced by
25% and all-cause mortality by 27%. Based on these strik-
ing outcomes, the 5-year trial was terminated prematurely
after only 3 years. While there is no doubt that these results
are truly impressive, they need to be appreciated in the
context of the study design. First, SPRINT enrolled
intermediate-high risk hypertensive patients, with no his-
tory of diabetes previous stroke, polycystic kidney disease,
or severe chronic kidney disease. Second, blood pressure
was measured using an automated office blood pressure
device in an unsupervised manner, a practice not routinely
used in standard clinical practice. Third, while the inten-
sively treated group had medications up-titrated to achieve
targets of <120 mm Hg, the control group had medications
down-titrated to attain targets of 140 mm Hg and perhaps
the worse outcomes in the control group may have been
due, in part, to withdrawal of cardioprotective medication.
Fourth, while a goal of <120 mm Hg was strived for, the
achieved mean systolic blood pressure was actually higher
(z122 mm Hg). Finally, in spite of the significant benefits
of lower blood pressure targets, there were some unfavor-
able consequences, including acute renal failure, electrolyte
disturbances, and hypotension, which were deemed by theAmerican Society of Hypertension. This is an open access article
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potential benefits.
Soon after the SPRINT findings were publicized, other
meta-analyses were published that also showed cardiovas-
cular benefit when systolic blood pressure was targeted to
levels <130 mm Hg.3–5 Taken together, the recent data
strongly suggest that patients with hypertension have less
cardiovascular events with lower morbidity and mortality,
if systolic blood pressure is maintained at 120–130 mm
Hg, rather than the currently accepted level of <140 mm
Hg. From a practical viewpoint, this translates to many
more patients requiring more medications with an increased
burden on already stressed health care systems. However,
the extra efforts and costs seem well worth the while
because the potential benefits of less morbidity of stroke,
heart failure, coronary events, and death translate to a
healthier population and a more productive society.6,7
Whether similar benefit will be evident for hypertension-
associated cognitive decline awaits confirmation when the
SPRINT mind study will be completed within the next year.
While SPRINT focused on treatment in already treated
high-risk hypertensive patients, the Heart Outcomes Pre-
vention Evaluation 3 study questioned whether antihyper-
tensive treatment in patients with high-normal blood
pressure and with no history of previous cardiovascular
events is associated with reduced major cardiovascular
morbidity and mortality.8 This study failed to show benefit
of antihypertensive treatment in these patients.
Taking into account the findings from the recent hyper-
tension studies, the overall message in nondiabetic hyper-
tensive patients could be summarized as: (1) strive for a
systolic blood pressure lower than the current recommen-
ded goal of 140 mm Hg, (2) targeting systolic blood pres-
sure levels of 120–130 mm Hg, especially in hypertensive
patients with significant risk factors and including the
elderly, is safe with demonstrated cardiovascular benefit,
(3) advantages of aggressive treatment to levels
<120 mm Hg are still unclear, and (4) in low risk patients
with high-normal blood pressure, lifestyle modifications
rather than initiation of antihypertensive treatment should
be advocated.
This has been an exciting and thought-provoking time for
the hypertension community, because the new evidence
from SPRINT and large meta-analyses, will likely lead to
changes in major hypertension guidelines, with the sugges-
tion that systolic blood pressure targets should be lower
than those currently recommended. This will require
increased clinical vigilance, more aggressive treatment
and, of major importance, continued efforts in stressing
healthy lifestyle choices. Moreover, as modern medicine
embraces ‘‘personalized’’ or ‘‘precision’’ medicine, it needs
to be stressed that it is essential to ‘‘personalize’’ care for
patients with hypertension because comorbidities and riskfactors such as diabetes, previous stroke, kidney disease,
ethnic background, age, and frailty will influence clinical
decisions on care and treatment. This is especially impor-
tant because many of these factors are not necessarily
accounted for in all clinical studies that form the basis of
evidence-based hypertension guidelines. Better manage-
ment of hypertensive patients aiming for a systolic blood
pressure lower than the currently recommended level of
140 mm Hg, and striving for 120–130 mm Hg, should pro-
tect against hypertension-associated adverse events with
less cardiovascular morbidity and mortality.Acknowledgments
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